CVC Capital completed the acquisition of the international women's health assets from Teva for $703m.

CVC Capital, a private equity and investment advisory firm, completed the acquisition of the international women's health assets from Teva, a generic medicines producer, for $703m. "We are very excited about the acquisition of this portfolio of dedicated women's healthcare products. Women's Health is a c.$30bn global industry and we look forward to expanding and investing in this portfolio to address an increasing number of women's health issues. Using our sector expertise and industry network, we will aim to transform this portfolio into a leading global women's healthcare platform through further investments and acquisitions," Cathrin Petty, CVC Partner and Head of European Healthcare.